• 1
    Sasnauskas K., Bulavaite A., Hale A., Jin L., Knowles W.A., Gedvilaite A., Dargeviciūte A., Bartkeviciūte D., Zvirbliene A., Staniulis J., Brown D.W., Ulrich R. (2002) Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae. Intervirology 45: 30817.
  • 2
    Yang R., Murillo F.M., Lin K.Y., Yutzy W.H. 4th, Uematsu S., Takeda K., Akira S., Viscidi R.P., Roden R.B. (2004) Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. J Immunol 173: 262431.
  • 3
    Koletzki D., Biel S.S., Meisel H., Nugel E., Gelderblom H.R., Krüger D.H., Ulrich R. (1999) HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein. Biol Chem 380: 32533.
  • 4
    Sedlik C., Saron M., Sarraseca J., Casal I., Leclerc C. (1997) Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 94: 5038.
  • 5
    Schwarz K., Meijerink E., Speiser D.E., Tissot A.C., Cielens I., Renhof R., Dishlers A., Pumpens P., Bachmann M.F. (2005) Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol 35: 81621.
  • 6
    Chen Y., Xiong X., Liu X., Li J., Wen Y., Chen Y., Dai Q., Cao Z., Yu W. (2006) Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system. Mol Immunol 43: 43642.
  • 7
    Garcea R.L., Gissmann L. (2004) Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol 15: 5137.
  • 8
    Wynne S.A., Crowther R.A., Leslie A.G. (1999) The crystal structure of the human hepatitis B virus capsid. Mol Cell 3: 77180.
  • 9
    Ulrich R., Nassal M., Meisel H., Kruger D.H. (1998) Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 50: 14182.
  • 10
    Pumpens P., Grens E. (2001) HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44: 98114.
  • 11
    Oliveira G.A., Wetzel K., Calvo-Calle J.M., Nussenzweig R., Schmidt A., Birkett A., Dubovsky F., Tierney E., Gleiter C.H., Boehmer G., Luty A.J., Ramharter M., Thornton G.B., Kremsner P.G., Nardin E.H. (2005) Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 73: 358797.
  • 12
    Zhang Y.L., Guo Y.J., Wang K.Y., Lu K., Li K., Zhu Y., Sun S.H. (2007) Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus. Scand J Immunol 65: 3208.
  • 13
    Song S., Wang Y., Zhang Y., Wang F., He Y., Ren D., Guo Y., Sun S. (2007) Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG. Cancer Lett 256: 90100.
  • 14
    Jiang L., Qian F., He X., Wang F., Ren D., He Y., Li K., Sun S., Yin C. (2007) Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice. J Gene Med 9: 25364.
  • 15
    Liang X., Qu Z., Zhang Z., Du J., Liu Y., Cui M., Liu H., Gao L., Han L., Liu S., Cao L., Zhao P., Sun W. (2008) Blockade of preS2 down-regulates the apoptosis of HepG2.2.15 cells induced by TRAIL. Biochem Biophys Res Commun 369: 45663.
  • 16
    Sadeyen J.R., Tourne S., Shkreli M., Sizaret P.Y., Coursaget P. (2003) Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology 309: 3240.
  • 17
    Karpenko L.I., Lebedev L.R., Ignatyev G.M., Agafonov A.P., Poryvaeva V.A., Pronyaeva T.R., Ryabchikova E.I., Pokrovsky A.G., Ilyichev A.A. (2003) Construction of artificial virus-like particles exposing HIV epitopes, and the study of their immunogenic properties. Vaccine 21: 38692.
  • 18
    Phelps J.P., Dang N., Rasochova L. (2007) Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis. J Virol Methods 141: 14653.
  • 19
    Barth H., Ulsenheimer A., Pape G.R., Diepolder H.M., Hoffmann M., Neumann-Haefelin C., Thimme R., Henneke P., Klein R., Paranhos-Baccalà G., Depla E., Liang T.J., Blum H.E., Baumert T.F. (2005) Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 105: 360514.
  • 20
    Moron VG, Rueda P, Sedlik C, Leclerc C (2003) In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 171: 224250.
  • 21
    Gedvilaite A., Dorn D.C., Sasnauskas K., Pecher G., Bulavaite A., Lawatscheck R., Staniulis J., Dalianis T., Ramqvist T., Schönrich G., Raftery M.J., Ulrich R. (2006) Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology 354: 25260.
  • 22
    Zhang R., Li M., Chen C., Yao Q. (2004) SHIV virus-like particles bind and activate human dendritic cells. Vaccine 23: 13947.
  • 23
    Beames B., Lanford R.E. (1995) Insertions within the hepatitis B virus capsid protein influence capsid formation and RNA encapsidation. J Virol 69: 683388.
  • 24
    Delaney W.E. 4th, Isom H.C. (1998) Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 28: 113446.